Kevin J. Harrington - Researcher Profile

Publications

2 shown

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness , Kevin J. Harrington , Richard Greil +97 more

2019 The Lancet 2928 citations

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen , Denis Soulières , Christophe Le Tourneau +97 more

There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour activity and manageabl...

2018 The Lancet 1593 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 3
Citations: 6,114
Institution: Institute of Cancer Research

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-6014-348X

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.